Interleukin 18 (IL-18) as a target for immune intervention. | Zendy

Sebastian Wawrocki | Zendy; Magdalena Druszczyńska | Zendy; Magdalena KowalewiczKulbat | Zendy; Wiesława Rudnicka | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Interleukin 18 (IL-18) as a target for immune intervention.

Author(s) -

Sebastian Wawrocki,

Magdalena Druszczyńska,

Magdalena KowalewiczKulbat,

Wiesława Rudnicka

Publication year - 2016

Publication title -

acta biochimica polonica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.452

H-Index - 78

eISSN - 1734-154X

pISSN - 0001-527X

DOI - 10.18388/abp.2015_1153

Subject(s) - cytotoxic t cell , immune system , cytokine , interleukin 15 , biology , immunology , cd8 , haematopoiesis , microbiology and biotechnology , innate immune system , interleukin 12 , innate lymphoid cell , interleukin , stem cell , in vitro , biochemistry

Interleukin 18 (IL-18) is a pleiotropic cytokine involved in the regulation of innate and acquired immune response. In the milieu of IL-12 or IL-15, IL-18 is a potent inducer of IFN-gamma in natural killer (NK) cells and CD4 T helper (Th) 1 lymphocytes. However, IL-18 also modulates Th2 and Th17 cell responses, as well as the activity of CD8 cytotoxic cells and neutrophils, in a host microenvironment-dependent manner. It is produced by various hematopoietic and nonhematopoietic cells, including dendritic cells and macrophages. In an organism, bioactivity of the cytokine depends on the intensity of IL-18 production, the level of its natural inhibitory protein - IL-18BP (IL-18 binding protein) and the surface expression of IL-18 receptors (IL-18R) on the responding cells. This review summarizes the biology of the IL-18/IL-18BP/IL-18R system and its role in the host defense against infections. The prospects for IL-18 application in immunotherapeutic or prophylactic interventions in infectious and non-infectious diseases are discussed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research